This is investment research, not personal financial advice.
Ramsay Health Care (ASX:RHC) rose A$6.04, or 13.7%, to A$50.06 on 27 August after its FY2026 result showed a 22.9% constant-currency increase in underlying profit and a cleaner Australian hospital recovery than the market had allowed for. The gain added about A$1.39 billion to the value implied by 229.93 million shares, a large response to A$58.8 million of extra underlying profit attributable to shareholders.
The arithmetic behind the response is better than that comparison suggests. Australian underlying EBIT grew 11.2%; theatre utilisation reached 70%; Funding Group leverage fell below 2 times; and the European holding that has obscured the core business is scheduled for a shareholder vote in November. Yet group accounting return on invested capital rose only 30 basis points to 4.6% (Ramsay 2026a; Ramsay 2026b). The result supports the direction of the rally. The post-result price also assumes that one year of operating repair becomes a multi-year cash and margin record.
The A$1.39 billion reaction had operating substance behind it
Revenue from contracts with customers rose 4.2% in constant currency to A$18.58 billion. Group underlying EBIT increased 11.8% to A$1.16 billion and underlying NPAT after non-controlling interests increased 22.9% to A$364.1 million. Fully diluted underlying EPS rose 27.0% in constant currency to A$1.51. Statutory NPAT increased from A$24.0 million to A$329.2 million, although most of that spectacular percentage reflects the A$291 million post-tax UK impairment booked in FY2025 rather than comparable operating growth (Ramsay 2026a).
The market did not mistake the impairment reversal for cash. The Australian Financial Review framed the move around Natalie Davis's strategic overhaul and the shares' surge, independently confirming that the operating change, rather than a mechanical accounting item, drove the session (AFR 2026). TradingView and Yahoo's daily series both recorded a A$50.06 close against A$44.02 on 26 August, a 13.72% move. TradingView's displayed basic market capitalisation lagged the new close, so the market capitalisation used here is the author-calculated A$11,510.3 million. The calculation multiplies the closing price by reported shares (TradingView 2026a).
A hospital result can look stronger merely because reimbursement catches up after a bad year. Ramsay had more than that. In Australia, activity grew 3.3%, the number of admitting visiting medical officers grew 3.3%, and utilisation improved by 90 basis points. Underlying EBIT margin expanded 30 basis points to 9.4% despite a net A$26 million funding hit at Joondalup Public Campus. Labour costs were flat as a percentage of revenue, excluding the Joondalup distortion, and supply costs fell as procurement shifted from hospital-by-hospital choices toward national tenders (Ramsay 2026b; Ramsay 2026c).
That combination explains why the reaction was roughly proportionate rather than obviously excessive. Volume, price and cost each contributed. The unanswered question is duration.
Ramsay earns on used theatre hours, not on hospital count
Ramsay treats patients across Australia, the United Kingdom and continental Europe. Its economics differ from those of a manufacturer with a discrete unit cost. A hospital carries expensive buildings, clinical equipment, leases and a large skilled workforce before the first case begins. Once staffing and safety requirements are met, an extra procedure in an available theatre can add revenue at a high marginal contribution. An empty room does the opposite.
The Australian network is the centre of that engine. Ramsay directs high-acuity work in cardiology, orthopaedics and oncology to large hospitals, recruits doctors who choose where to admit patients, negotiates payment with private health insurers, and fills the available sessions. Five major hospitals already run at roughly 80% to 85% theatre utilisation, which management described as global sector practice. The network average was only 70% in FY2026, up from 69%, even after Ramsay opened 22 theatre and procedure rooms (Ramsay 2026c).
That gap matters more than another logo on the hospital list. Existing capacity can absorb extra cases without a matching increase in property cost. Management has therefore linked new capacity to site-level utilisation and will add 11 theatres or catheter laboratories in FY2027, including at Hollywood, St George and Westmead. Australian capital expenditure was A$365 million in FY2026, below the original A$410 million to A$440 million plan partly because development timing moved and landlords reimbursed A$30.8 million (Ramsay 2026c).
The doctor network is part of the barrier to entry. Ramsay's catchment and referral data tell hospital managers where a specialist or service line can fill idle sessions. Its scale also supports national procurement and insurer negotiation. Four insurer agreements, covering about 48% of private-insurance revenue, now map annual indexation toward sector cost measures. That is progress, not complete protection: management said labour costs are growing about 5%, with state enterprise agreements carrying further increases through FY2028 (Ramsay 2026c).
Demand is not the immediate constraint. APRA reported 12.82 million people with hospital cover at 30 June 2026, 45.8% of the population, while annual hospital benefits paid rose from A$19.1 billion to A$19.9 billion. Hospital treatment membership increased from 12.53 million to 12.82 million over the year (APRA 2026). The broader pool is large too: Australian health spending was A$270.5 billion in 2023-24, or 10.1% of GDP, with non-government spending growing 3.7% (AIHW 2025). Ramsay's problem has been converting that demand into returns after labour inflation, weak public tariffs and years of capital expenditure.
Five years of growth did not produce a straight profit line
The history table uses statutory NPAT because that is the clean audited series. It is deliberately ugly. FY2024 includes A$618.1 million of profit from selling Ramsay Sime Darby. FY2025 includes the UK impairment. Those items explain the 2024 spike and 2025 collapse; they do not describe hospital earning power. Revenue, cash flow and accounting ROIC are more useful beside them (Ramsay 2024; Ramsay 2025a).
| A$m unless stated | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue from customers | 13,312.4 | 14,963.9 | 16,660.2 | 17,673.8 | 18,577.8 |
| Statutory NPAT after non-controlling interests | 274.0 | 298.1 | 888.7 | 24.0 | 329.2 |
| Operating cash flow | 715.5 | 1,279.6 | 1,292.8 | 1,480.8 | 1,430.7 |
| Capital expenditure | 708.5 | 720.9 | 753.8 | 776.6 | 734.2 |
| Accounting ROIC | 3.6% | 4.4% | 4.3% | 4.3% | 4.6% |
| Funding Group leverage | 3.3x | 3.2x | 2.00x | 2.18x | 1.83x |
| Author calculation: OCF less capex | 7.0 | 558.7 | 539.0 | 704.2 | 696.5 |
Sources: Ramsay's FY2022, FY2023, FY2024, FY2025 and FY2026 filings (Ramsay 2022; Ramsay 2023; Ramsay 2024; Ramsay 2025a; Ramsay 2026a). OCF less capex is author-calculated. Ramsay explicitly reported FY2026 free cash flow of A$696.5 million using the same subtraction. The ROIC series is management-computed from underlying EBIT after tax and average invested capital; it is reported by Ramsay rather than independently reconstructed here.
Revenue compounded while the return did not. The FY2022 acquisition of Elysium, pandemic disruption, heavy capital spending and weak European reimbursement consumed much of the benefit. Accounting ROIC recovered from 3.6% to 4.6% over four years, but that remains low for an equity-funded owner and below the cost of capital implied by Ramsay's own debt and equity risk.
The peer check sharpens the point without pretending the definitions are identical. UK hospital operator Spire Healthcare reported an 8.0% FY2025 return on capital employed and a 17.9% hospital adjusted EBITDA margin. Its ROCE excludes different items and its payer mix is not Ramsay's, so the numbers are directional. They still show that a hospital estate can produce a mid-to-high single-digit accounting return under similar labour and tariff pressure (Spire 2026).
Ramsay has a stronger internal measure in Funding Group ROCE, which reached 14.8%. That excludes Ramsay Sante and is calculated before goodwill, while the 4.6% group ROIC includes a broader invested-capital denominator. Both are reported measures. The wide gap is the point: the operating core has improved, but acquisition goodwill, consolidated Europe and capital already sunk into the estate still weigh on what the whole company earns.
Australia supplied the clean part of the surprise
Australia generated A$639.8 million of underlying EBIT, up 11.2%, from revenue growth of roughly 8%. Underlying EBIT margin reached 9.4%. Like-for-like admissions grew about 3%; revenue indexation, acuity and mix supplied the rest. The extra revenue arrived while labour held flat as a percentage of revenue and consumable costs declined as a percentage of revenue (Ramsay 2026b; Ramsay 2026c).
The operating detail makes this more credible than a single margin line. Ramsay closed four sites, put surplus land up for sale, cut agency use, and rolled catchment, theatre and robotics data into hospital decisions. A new procurement dashboard identifies equivalent consumables and the saving available if a hospital changes supplier. These are small, repeatable decisions across a large network, not a promise that one central project will transform every facility.
There is counter-evidence. Ramsay added 22 procedure rooms during FY2026, so some fixed-cost absorption reflects capacity that has not yet reached a steady run rate. FY2027 includes A$10 million to A$15 million of additional technology and transformation operating expense. The patient administration and rostering systems will roll out hospital by hospital and management said benefits will take time. Queensland's proposed enterprise agreement provides a 14% increase over four years, New South Wales is entering negotiation, and Victoria carries a larger step-up later in the cycle (Ramsay 2026c).
Insurer indexation also carries concentration risk. A hospital cannot simply raise a posted price. It negotiates with payers whose own members resist premium increases. The indexed contracts covering 48% of private-insurance revenue reduce the annual cliff, but half the pool remains outside that structure. APRA's growth in insured people and benefits supports volume; it does not guarantee that hospital reimbursement keeps pace with nurses, specialists, consumables and compliance.
The Australian moat is therefore stable, with one part widening. The footprint, doctor relationships and clinical capability are hard to reproduce. National procurement and operating data are starting to make scale pay. The low group return says the moat has not yet translated into owner economics across the entire capital base.
Cash recovered faster than the accounting return
The owner-cash bridge begins with A$1.43 billion of group operating cash flow. Subtract A$734.2 million of capital expenditure and FY2026 free cash flow was A$696.5 million. That was A$7.7 million below FY2025 even though underlying EBIT rose A$119.6 million, because Ramsay Sante had an adverse working-capital movement tied to French government payments (Ramsay 2026a).
Group free cash flow is not all available to RHC ordinary shareholders. Ramsay consolidates 100% of Ramsay Sante while owning 52.79%; minorities own the rest. It also includes maintenance, compliance and growth expenditure in one capex number. A stricter post-separation proxy is Funding Group free cash flow, which rose from A$58.7 million to A$382.4 million as Australia and both UK businesses became cash-flow positive. That compares with A$398.4 million of Funding Group underlying NPAT, a much cleaner conversion than the consolidated number suggests (Ramsay 2026b).
Funding Group leverage fell from 2.18 times to 1.83 times and interest cover reached 8.94 times. Liquidity was A$1.07 billion before the A$251 million acquisition of National Capital Private Hospital. Management expects leverage to remain below 2.5 times after completion, with about 60% of FY2027 debt hedged and a weighted average cost near 5.5% (Ramsay 2026c).
The balance sheet is no longer the immediate bear case. Capital allocation is. The group spent between A$708.5 million and A$776.6 million each year in the table, yet ROIC stayed around 4%. National Capital adds another asset before Ramsay has shown that the broader return can approach Funding Group ROCE. The more disciplined FY2026 pattern, lower development spend, site closures and capex directed toward utilised procedural capacity, is encouraging. One year does not settle the record.
The Sante distribution changes what one RHC share contains
Ramsay proposes to distribute its 52.79% interest in listed Ramsay Generale de Sante to RHC shareholders. The vote is scheduled for 24 November 2026 and completion for December. It is an in-specie distribution, not a cash disposal: an RHC investor would retain an interest in the independently financed European business while RHC's financial statements deconsolidate it. Ramsay Sante already has separate management, financing and balance-sheet arrangements, which reduces operating separation work (Ramsay 2026b; Ramsay 2026c).
The distribution removes accounting fog rather than economic exposure. Ramsay Sante's FY2026 underlying EBIT rose 11.1% to A$330.8 million, but France remained loss-making below EBIT because tariffs failed to cover costs and tax included the French CVAE levy. The subsidiary refinanced EUR1.75 billion of senior debt to 2033; bank leverage was 4.7 times and liquidity EUR487 million at June (Ramsay 2026c). Those obligations sit with Sante, but the distributed shares still carry their economics.
A quoted-price marker gives the stake about A$1.04 billion of equity value. Ramsay Generale de Sante closed at EUR11 with 110.35 million shares; 52.79% translated at EUR1=A$1.62169 is roughly A$4.52 for each RHC share. This is an author calculation from a very thinly traded security, with only 26 shares recorded in the snapshot, so it is a marker rather than a clean appraisal (TradingView 2026b).
The structure matters to valuation. Subtracting A$4.52 from RHC's A$50.06 leaves A$45.54 for the Funding Group. FY2026 Funding Group NPAT was A$398.4 million, or about A$1.73 per fully diluted RHC share. The residual therefore trades near 26.4 times that earnings base. That multiple says the market expects Australian and UK improvement to survive the separation.
A$50.06 sits inside the recovery case, not outside it
A sum-of-the-parts range fits the business better than a single group P/E because the shareholder is scheduled to receive two listed exposures. The first part applies a multiple to Funding Group earnings. The second adds a per-RHC-share value for the Sante distribution. The EUR11 market marker is one reference, not a fixed input.
The severe case assumes Funding Group EPS of A$1.40 to A$1.50, a 17 to 19 times multiple, and only A$2 to A$3 for Sante. That produces A$25.80 to A$31.50. It captures a wage and tariff squeeze, lower utilisation, transaction slippage and a further European equity decline.
The bear case uses A$1.55 to A$1.70 of Funding Group EPS at 20 to 22 times plus A$3 to A$4 for Sante, giving A$34.00 to A$41.40. The base case assumes Australian margin improvement continues but remains gradual, with Funding Group EPS of A$1.75 to A$1.95, a 24 to 27 times multiple and A$4 to A$5 for Sante. Its range is A$46.00 to A$57.60. The bull case requires A$2.05 to A$2.20 of EPS, a 28 to 31 times multiple and A$5 to A$6 for Sante, producing A$62.40 to A$74.20.
The post-result A$50.06 price is in the lower half of the base range. It no longer prices the FY2025 impairment year. It prices continued Australian margin work and gives little weight to a return to the old 3.6% ROIC trough.
A sensitivity table shows the two variables doing most of the work. Each cell adds the A$4.52 Sante market marker to Funding Group EPS times the selected multiple.
| Funding Group EPS | 20x | 24x | 28x | 32x |
|---|---|---|---|---|
| A$1.60 | A$36.5 | A$42.9 | A$49.3 | A$55.7 |
| A$1.80 | A$40.5 | A$47.7 | A$54.9 | A$62.1 |
| A$2.00 | A$44.5 | A$52.5 | A$60.5 | A$68.5 |
| A$2.20 | A$48.5 | A$57.3 | A$66.1 | A$74.9 |
The cash reverse-check is sterner. After subtracting the A$1.04 billion Sante marker, the residual equity value is about A$10.47 billion. Funding Group FY2026 free cash flow of A$382.4 million is a 3.65% cash yield. A perpetuity using a 9.5% cost of equity would need about 5.6% annual growth from that cash base. Normalising working capital or allowing recent capex to mature reduces the implied growth, but the exercise shows how much future conversion sits inside the price.
Wages, tariffs and capital discipline form the anti-thesis
The strongest disconfirming fact is not France. It is that A$18.58 billion of revenue and years of heavy investment produced a 4.6% group accounting ROIC. A business can report higher underlying earnings while destroying value if each dollar of growth needs too much property, equipment and working capital.
Three operating risks could preserve that gap. First, labour indexation can outrun insurer and government reimbursement. Ramsay's Australian wages are growing about 5%, Victoria has a larger contracted step-up later in the cycle, UK NHS tariff indexation remains weak, and France has already shown the damage when public rates trail cost. Second, utilisation gains can stall as new rooms open. A 70% network average leaves room, but the best hospitals are already near 80% to 85%, so growth capital must move to the right catchments. Third, technology spend can arrive before the revenue-cycle and rostering benefits (Ramsay 2026c).
The capital-allocation record adds another risk. Elysium required site and ward closures after its acquisition. Ramsay Sime Darby was sold. The group is distributing Sante after years of consolidated complexity. National Capital may strengthen the Canberra network, but it also puts A$251 million back to work before group ROIC has cleared 5%. Management's current discipline is visible in lower development capex, asset sales and a 1.83 times leverage ratio. The evidence is recent.
The anti-thesis does not deny the FY2026 improvement. It says the market has shifted from doubting recovery to assuming persistence. If Australian EBIT margin returns below 9.2%, employee cost rises more than 50 basis points relative to revenue, or Funding Group leverage moves above 2.3 times after National Capital, the persistence assumption weakens. If utilisation rises above 72% while margin and cash conversion remain intact, the fixed-cost engine is doing more of the work.
November separates the operating story from the European one
The next two dates are unusually useful. The 24 November shareholder vote determines whether Sante leaves Ramsay's consolidated accounts. The scheme booklet must set out demerger costs, tax consequences and any liabilities that remain. Six days later, management's investor day should provide the first detailed operating plan for the simpler Funding Group (Ramsay 2026b; Ramsay 2026c).
The February 2027 half-year result then tests the harder claims. Australian theatre utilisation needs to remain at least 70% as recently opened rooms mature. Underlying EBIT margin needs to remain above 9.2% despite additional technology expense. Funding Group leverage needs to stay below 2.3 times after National Capital. And operating cash should track the earnings improvement rather than repeat Sante's FY2026 working-capital drag.
The 13.7% rally corrected an overly low reading of Ramsay's Australian recovery. At A$50.06, the market now prices a different proposition: theatre utilisation keeps rising, margin gains survive wage resets, Sante separates on schedule, and better Funding Group cash eventually lifts the 4.6% group return. November will simplify the structure. The half-year cash flow will show whether the economics simplified with it.
Source notes
Evidence confidence is partial. The FY2026 filing, presentation, transcript and five-year history were fetched and reconciled. TradingView and Yahoo agreed on the A$50.06 close, A$44.02 previous close and 13.72% move, but the Finance API's ASX price series stopped at 21 August and its filings stopped at 22 July. TradingView's basic market-cap field also lagged the new price, so the stated A$11.51 billion market capitalisation is calculated from close and shares.
Missing information is concentrated in the separation. The Sante scheme booklet had not been released at the ASX close, so demerger costs, tax details and any retained liabilities are not included in the ranges. The Sante marker rests on an illiquid EUR11 quote and should be read as a sensitivity input. Management reports ROIC and Funding Group ROCE on different capital bases, which prevents a like-for-like return bridge.
References
- ASX 2026: Ramsay Health Care Limited company page and issuer identity.
- TradingView 2026a: ASX:RHC market close, move and shares snapshot, 27 August 2026.
- Ramsay 2026a: FY2026 Appendix 4E and full-year financial results.
- Ramsay 2026b: FY2026 investor presentation and results briefing speech.
- Ramsay 2026c: FY2026 full-year results call transcript.
- Ramsay 2026d: 2026 half-year results presentation.
- Ramsay 2025a: corrected FY2025 Annual Report.
- Ramsay 2025b: FY2025 results presentation and speech.
- Ramsay 2024: FY2024 Annual Report.
- Ramsay 2023: FY2023 Appendix 4E and full-year results.
- Ramsay 2022: FY2022 Appendix 4E and full-year results.
- AFR 2026: Australian Financial Review report on Ramsay's result-day surge and strategic overhaul.
- AIHW 2025: Health expenditure Australia 2023-24.
- APRA 2026: June 2026 private health insurance membership and benefits summary.
- Spire 2026: Spire Healthcare Group FY2025 full-year results.
- TradingView 2026b: Euronext:GDS price and shares snapshot, 27 August 2026.